Goal 3: Advance Translational Research

The Investigator's Catch-22: How Can NHLBI Help?

The Critical Challenge is to determine how NHLBI can continue to foster the translational research necessary to allow our researchers to further develop their NHLBI-funded basic science discoveries. Researchers can't readily get a "typical" grant to perform the preclinical and early clinical translational IND-enabling research, and also can't yet attract private sector support without having done the work to "de-risk" ...more »

Submitted by (@nhlbiforumadministrator1)

Voting

10 net votes
21 up votes
11 down votes
Active

Goal 3: Advance Translational Research

Next Stage of COPD Discovery

1) Refinement of COPD subphenotypes for therapeutics, diagnostics and mechanistic interrogation. The NIH should encourage a strong focus on a) rigorous, mechanistically-reinforced definitions (chronic bronchitis, emphysema (with and without obstruction), frequent exacerbators, combined pulmonary fibrosis and emphysema) and 2) the development and optimization of animal model systems that replicate the different subphenotypes. ...more »

Submitted by (@lungmatbio1)

Voting

16 net votes
26 up votes
10 down votes
Active

Goal 3: Advance Translational Research

NIH should promote, rather than deter “fast-track” translational research projects

In the current environment, NIH reviewers actually deter, rather than promote, progress on proposed pre-clinical animal research that is most likely to rapidly translate into clinical breakthroughs in the short term. Scientists should be allowed to focus on critical missing information (roadblocks) needed to accelerate a promising treatment to clinical trials. For instance, at the NHLBI there is currently no study section ...more »

Submitted by (@nhlbiforumadministrator)

Voting

9 net votes
18 up votes
9 down votes
Active

Goal 3: Advance Translational Research

NEW INFRASTRUCTURE FOR CLINICAL RESEARCH IN SLEEP AND CIRCADIAN DISORDERS

Much of the current clinical research on sleep and circadian research depends on cohorts designed for other purposes. While this has been helpful, such studies have limitations. These limitations are related to availability of in-depth phenotyping data and questions as to whether individuals identified in population studies are equivalent to those who present clinically with specific disorders. These concerns could ...more »

Submitted by (@jnoel0)

Voting

126 net votes
186 up votes
60 down votes
Active

Goal 2: Reduce Human Disease

Data from regulatory studies a barrier to evidence-based medicine

Alignment of regulatory, healthcare, and research arms of the government is poor. There is a need to improve the design, quality and usefulness of data from regulatory studies to address major clinical questions and also to facilitate scientific inquiry. This is a barrier to evidence based medicine and improved treatments.

Submitted by (@societyforvascularsurgery)

Voting

2 net votes
3 up votes
1 down votes
Active

Goal 3: Advance Translational Research

Substituting scientific-medical insight before profit in drug development

Since the Pure Food and Drug Act of 1906 and the rise of the FDA, the US federal government has directly inserted itself into medical research, primarily from a business perspective. The Orphan Drug Act of 1983 monetarily incentivized the process for rare diseases, but for ultra-rare diseases of < 1,000 patients, it does not work. Successful drugs for rare diseases have enormous price tags to compensate their development ...more »

Submitted by (@mtothbsf)

Voting

6 net votes
11 up votes
5 down votes
Active

Goal 3: Advance Translational Research

Cohort studies and clinical trials in vascular disease

Utilization of well characterized cohort studies and clinical trials to conduct ancillary scientific studies on pathophysiology, responses to treatment, and identify new ways to predict and treat disease. Restore the Ancillary Studies mechanism. Improved biobanks and data sharing platforms are needed. Facilitate public-private partnerships.

Submitted by (@societyforvascularsurgery)

Voting

2 net votes
3 up votes
1 down votes
Active

Goal 3: Advance Translational Research

Translational Cardiovascular Medicine

There is a need for the NHLBI to catalyze the development of tools and shared data resources to facilitate mechanistic studies in a human model system. This includes the ability to culture human cardiac tissue, as well as generate a resource to systematically characterize and catalog the epigenome and histone marks associated with the transcriptome in normal and diseased heart tissues.

Submitted by (@stacey.rentschler)

Voting

6 net votes
10 up votes
4 down votes
Active